Mental Health Disorders-Focused MIRA Pharmaceuticals Unveils Additional Preclinical Data

Like
1
Favorite

Mental Health Disorders-Focused MIRA Pharmaceuticals Unveils Additional Preclinical Data

Benzinga07-26

MIRA Pharmaceuticals Inc (NASDAQ:MIRA) stock is trading higher on Thursday, with a strong session volume of 47.90 million, according to data from Benzinga Pro. The company announced new insights from ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（1）

AVPK729
·07-31
This could be a very important discovery
Reply
Like
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2454860493?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/WAf6FM3JwBBtrCQ6eRxc1A--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/21a769afa6f8133f22c12cd9c3948af3","is_english":true,"pubTime":"2024-07-26 03:24","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2454860493","market":"us","top_or_hot":-1,"title":"Mental Health Disorders-Focused MIRA Pharmaceuticals Unveils Additional Preclinical Data","media":"Benzinga","content":"<div>\n<p>MIRA Pharmaceuticals Inc (NASDAQ:MIRA) stock is trading higher on Thursday, with a strong session volume of 47.90 million, according to data from Benzinga Pro.\nThe company announced new insights from ...</p>\n\n<a href=\"https://finance.yahoo.com/news/mental-health-disorders-focused-mira-192400636.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mental Health Disorders-Focused MIRA Pharmaceuticals Unveils Additional Preclinical Data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMental Health Disorders-Focused MIRA Pharmaceuticals Unveils Additional Preclinical Data\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-26 03:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/mental-health-disorders-focused-mira-192400636.html><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>MIRA Pharmaceuticals Inc (NASDAQ:MIRA) stock is trading higher on Thursday, with a strong session volume of 47.90 million, according to data from Benzinga Pro.\nThe company announced new insights from ...</p>\n\n<a href=\"https://finance.yahoo.com/news/mental-health-disorders-focused-mira-192400636.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://finance.yahoo.com/news/mental-health-disorders-focused-mira-192400636.html","article_id":"2454860493","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/WAf6FM3JwBBtrCQ6eRxc1A--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/21a769afa6f8133f22c12cd9c3948af3"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2454860493","pubTimestamp":1721935440,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"MIRA Pharmaceuticals Inc  stock is trading higher on Thursday, with a strong session volume of 47.90 million, according to data from Benzinga Pro.The company announced new insights from additional recently received preclinical study data regarding the mechanism of action and toxicology data for its novel oral ketamine analog, Ketamir-2.Ketamir-2 is MIRA’s drug candidate being investigated as a potential treatment forneurological and neuropsychiatric disorders.The new preclinical study results announced are the latest in a string of research developments progressing MIRA’s goal of submitting an Investigational New Drug Application  to the FDA for Ketamir-2 later this year.The latest preclinical data reveals that Ketamir-2 is a selective inhibitor of the NMDA receptor of glutamate, the primary excitatory neurotransmitter in the human brain, specifically interacting at the PCP-binding site of the NMDA complex.Ketamir-2 has a 30-50-fold lower affinity to the PCP site than ketamine.These fi","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","MIRA":"Mira Pharma"},"translate_title":"专注于精神健康障碍的MIRA Pharmaceuticals公布了更多临床前数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MIRA":1},"content_text":"MIRA Pharmaceuticals Inc (NASDAQ:MIRA) stock is trading higher on Thursday, with a strong session volume of 47.90 million, according to data from Benzinga Pro.\nThe company announced new insights from additional recently received preclinical study data regarding the mechanism of action and toxicology data for its novel oral ketamine analog, Ketamir-2.\nKetamir-2 is MIRA’s drug candidate being investigated as a potential treatment for neurological and neuropsychiatric disorders. \nRelated: Nano-Cap MIRA Pharmaceuticals’ Oral Ketamine Analog Shows Potential In Neuropsychiatric Disorders.\nThe new preclinical study results announced are the latest in a string of research developments progressing MIRA’s goal of submitting an Investigational New Drug Application (NDA) to the FDA for Ketamir-2 later this year.\nThe latest preclinical data reveals that Ketamir-2 is a selective inhibitor of the NMDA receptor of glutamate, the primary excitatory neurotransmitter in the human brain, specifically interacting at the PCP-binding site of the NMDA complex.\nKetamir-2 has a 30-50-fold lower affinity to the PCP site than ketamine.\nThe lower affinity is important because compounds may affect neurobehavioral functions at high affinity, potentially leading to side effects such as dissociation and hallucinations.\nUnlike traditional ketamine, which also affects several other sites on the NMDA receptor and interacts with opioid receptors, dopamine and serotonin transporters, and various acetylcholine receptors, Ketamir-2 exhibits unique selectivity and does not interact with these additional receptor sites.\nRecently conducted toxicology studies in rats and dogs have shown no toxicity at very high doses of Ketamir-2.\nThese findings underscore Ketamir-2’s favorable safety margin, further supported by its antidepressant and anxiolytic activities observed at oral doses five to tenfold lower than those tested in the toxicology studies.\nThe company says that Ketamir-2 could potentially be beneficial in treating conditions like depression, treatment-resistant depression (TRD), and post-traumatic stress disorder (PTSD).\nPrice Action: MIRA stock is up 38.8% at $3.27 at last check Thursday.\nRead Next:\n\nAbbVie’s Q2 Earnings Beat Estimates, Raises Annual Profit On Strong Sales From Newer Immunology And Cancer Drugs\n\n\"ACTIVE INVESTORS' SECRET WEAPON\" Supercharge Your Stock Market Game with the #1 \"news & everything else\" trading tool: Benzinga Pro - Click here to start Your 14-Day Trial Now!\nGet the latest stock analysis from Benzinga?\n\nThis article Mental Health Disorders-Focused MIRA Pharmaceuticals Unveils Additional Preclinical Data originally appeared on Benzinga.com\n© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"Product Release","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[{"id":333152661614640,"gmtCreate":1722364239343,"gmtModify":1722364243228,"author":{"id":"4122184555789872","authorId":"4122184555789872","name":"AVPK729","avatar":"https://community-static.tradeup.com/news/095332788dd585c4a74375b19d6443a0","vip":1,"crmLevel":4,"crmLevelSwitch":1,"idStr":"4122184555789872","authorIdStr":"4122184555789872"},"htmlText":"This could be a very important discovery","listText":"This could be a very important discovery","text":"This could be a very important discovery","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/333152661614640","repostId":2454860493,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":0,"commentSize":1,"repostSize":1,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}